GlassScriptPhysician profile
Arthur B Epstein
NPI 1427038249
$278,991.62
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
See the full distribution for Corneal and Contact Management
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97K · 2020: $126K · 2021: $44K · 2022: $12K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100,915.20 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $55,582.19 | 2019-2022 | |
| Lumenis, INC | $30,953.81 | 2019-2021 | |
| Shire North American Group INC | $24,016.88 | 2019 | |
| Sight Sciences, INC. | $17,368.37 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $11,169.65 | 2022 | |
| Sun Pharmaceutical Industries INC. | $8,428.34 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $6,933.79 | 2019-2021 | |
| Alcon Vision LLC | $6,221.26 | 2019-2022 | |
| Allergan, INC. | $4,926.72 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $4,430.82 | 2019-2021 | |
| Biotissue Holdings INC. | $2,115.91 | 2020-2021 | |
| Oculus, INC. | $2,000.00 | 2020 | |
| Lumenis (Germany) Gmbh | $1,500.00 | 2021 | |
| Lumenis LTD. | $1,500.00 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $714.60 | 2019-2022 | |
| Coopervision INC. | $96.03 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $24.88 | 2019 | |
| The Walman Optical Company | $23.81 | 2019 | |
| Maculogix, INC. | $21.53 | 2021 | |
| Akorn Operating Company LLC | $18.10 | 2021 | |
| Quidel Corporation | $17.76 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $11.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.